CD274 and cancer: In cancer patients with preexisting autoimmune disorders, including type 1 diabetes mellitus, the use of PD-1 and PDL-1 ICI antibodies, in particular, is frequently associated with development of mild IRAEs, which are usually easily managed and do not require treatment discontinuation, with a significant proportion of patients attaining clinical responses (48–51).